Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
124.80    1.00 (0.81%)
Bid:
124.60
Ask:
125.00
Spread: 0.40 (0.321%)
Market Cap: £303.79m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.5 (EPT/RI)

10 Oct 2022 09:18

RNS Number : 3204C
Liberum Capital Limited
10 October 2022
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

PureTech Health plc

(d) Date dealing undertaken:

07th October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

 

Purchase

 

14,664

 

2.21

 

2.2

 

ORD 25p

 

 

Sale

 

14,664

 

2.21

 

2.2

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

10th October 2022

 

Contact name:

Kristina Kapur

Telephone number:

020 3100 2034

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIBDGLBBDGDG
Date   Source Headline
9th Apr 20204:35 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSFinal Results
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:16 amRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
10th Mar 202010:00 amRNSGelesis: World’s Most Innovative Companies List
10th Mar 20207:00 amRNSNotice of Results
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:02 pmRNSPrice Monitoring Extension
5th Mar 20204:40 pmRNSSecond Price Monitoring Extn
5th Mar 20204:35 pmRNSPrice Monitoring Extension
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:36 pmRNSPrice Monitoring Extension
3rd Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSClinical Trial Initiated Of Wholly-Owned Candidate
2nd Mar 20207:00 amRNSTotal Voting Rights
27th Feb 20204:41 pmRNSSecond Price Monitoring Extn
27th Feb 20204:36 pmRNSPrice Monitoring Extension
25th Feb 20207:00 amRNSAkili ADHD Study in The Lancet Digital Health
18th Feb 20207:00 amRNSPRTC to Present at Leerink Healthcare Conference
3rd Feb 20204:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20204:35 pmRNSPrice Monitoring Extension
3rd Feb 20207:00 amRNSTotal Voting Rights
23rd Jan 20207:00 amRNSPureTech Receives $200M from KRTX Shares
15th Jan 20201:04 pmRNSAkili's New ADHD Trial Met Primary Endpoint
13th Jan 202012:07 pmRNSSecond Price Monitoring Extn
13th Jan 202012:02 pmRNSPrice Monitoring Extension
2nd Jan 20207:00 amRNSTotal Voting Rights
19th Dec 20197:00 amRNSFollica Positive Androgenetic Alopecia Study
17th Dec 201912:00 pmRNSGelesis Partners with US Telehealth Provider
12th Dec 20191:04 pmRNSAkili Meets Primary Endpoint in MDD Clinical Trial
10th Dec 201912:02 pmRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSVedanta & BMS Begin Immuno-Oncology Clinical Study
9th Dec 20197:00 amRNSGelesis Attracts $84M in New Capital for Launch
5th Dec 20197:00 amRNSVedanta MultiDrug Resistance Program Granted $5.8M
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 201912:02 pmRNSPrice Monitoring Extension
21st Nov 20197:00 amRNSKaruna Prices $250M Follow-On Offering
18th Nov 201911:03 amRNSKaruna Successful Ph2 Schizophrenia Study Readout
15th Nov 201912:51 pmRNSresTORbio Update on Phase 3 Trial
13th Nov 20197:00 amRNSPureTech to Present at Jefferies London Conference
5th Nov 20191:00 pmRNSPRTC Presents Novel Oncology Program Data at SITC
5th Nov 201911:00 amRNSGelesis Shares New Plenity Safety & Efficacy Data
28th Oct 201912:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.